newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™